Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
  • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
  • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/10—Transferases (2.)
  • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
  • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
  • C12N9/1211—Thymidine kinase (2.7.1.21)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5258—Virus-like particles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
  • A61K2039/6031—Proteins
  • A61K2039/6075—Viral proteins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
  • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/16011—Human Immunodeficiency Virus, HIV
  • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
  • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2810/00—Vectors comprising a targeting moiety
  • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
  • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
  • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
  • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Definitions

• the present invention relates to a fusion protein comprising HIV-I Nef mutant and its use in therapy and diagnosis, particularly, but not exclusively in the field of cancer, and infectious diseases.
• Protein delivery into eukaryotic cells is a field of investigation having a great deal of potential applications.
• the general aim is delivering selected molecules, like drugs or prodrug modifying enzymes, to appropriate cell targets.
• the technical procedures currently available rely on the ability of liposomes (1) and nanoparticles (2) to be internalized by cells.
• Other approaches exploit the unusual properties of some cellular or viral proteins to actively cross the cell membrane, as for Drosophila antennapedia homeotic transcription factor (3), basic Fibroblast Growth Factor (4), Human
• HIV Immunodeficiency Virus
• HSV Herpes Simplex Virus
• HSV Herpes Simplex Virus
• PreS2 Hepatitis B Virus PreS2
• VLPs have been already generated by engineering the genomes of a wide number of virus species, including Human Papilloma virus (9, 10), Human Hepatitis B and C virus (11, 12) retroviruses (13) and lentiviruses (for a review, see 14).
• HSV-I TK was delivered to cells upon fusion with 11 amino acids from the basic domain of HIV-I Tat, which impart cell membrane translocating ability (15).
• Another approach attempted to deliver HSV- 1 TK upon the formation of complexes with protein-lipid artificial structures (16).
• neither approach guarantees the cell targeting selectivity, which may be achieved by expressing the appropriate receptor in packaging cells.
• Nef acts as an enhancer of the viral infectivity. While previous observations suggested that the expression of Nef in the producer cells increases the retrotranscription activity in the target cells, more recent papers suggested that Nef acts by increasing the viral infectivity through the stimulation of the intravirion retrotranscription activity, or by increasing the cytoplasmic delivery of virions through a mechanism acting at the level of viral entry. Finally, the possibility that Nef influences the functions of the viral envelope has been also proposed.
• Nef7 may be incorporated into virion.
• all wild type (wt) Nef isoforms are expected to be incorporated in virions, there is no data in the literature describing Nef alleles with increased virion incorporation activity.
• the high levels of Nef7 virion incorporation described herein is surprising.
• non-structural proteins like Vif, Vpr, and Nef are incorporated in viral particles (for reviews, see 18, 19 and 20). In general, the respective amounts appear too limited to allow efficient protein delivery strategies.
• Vpr a number of papers reporting the efficient packaging of Vpr with either a bacterial nuclease (21), GFP or CAT proteins (21-24), with the C-terminal part of HIV-I Vpu protein (24), or with single-chain antibodies (24), have been published.
• large bodies of evidence demonstrated that the incorporation of Vpr-fusion proteins can lead to a severe reduction of the virus infectivity by targeting multiple steps of viral morphogenesis (22, 23).
• Nef7-related fusion products in packaging cells did not appear to hinder either the production or the infectivity of the lentiviral virions.
• Vpr has apoptotic/cell-cycle arresting activities (for a review, see 25), we detected no major anti-cellular effects were by Nef7.
• Nef7 based VLP targeted to HIV infected cells may be used in the treatment of persistently HIV-I infected cells, that in AIDS patients represent virus reservoirs resistant to HAART therapies.
• a fusion protein comprising a Nef double mutant (V 153 L, E 177 G) polypeptide (hereinafter Nef7) as shown in Seq ID No: 1 associated with a heterologous polypeptide.
• heterologous polypeptide is associated with the C terminus of Nef7.
• heterologous polypeptide is a therapeutic or diagnostic polypeptide.
• the therapeutic polypeptide is a tumor antigen selected from the group consisting of BAGE-I, GAGE-I, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GnTV f , HERV-K-MEL, KM-HN-I, LAGE-I, MAGE-Al, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-AlO, MAGE- A12, MAGE-C2, MART-I, mucin k , NA-88, NY-ES O- l/LAGE-2, SAGE 5 SpI 7, SSX- 2, SSX-4TRP2-INT2 g tumor antigens.
• the tumor antigen is MAGE-A3
• the therapeutic polypeptide is an enzyme capable of converting a non-toxic prodrug into an active cytotoxic drug selected from the group consisting of : a) Herpes Simplex Virus derived Thimidine Kinase (TK) b) E.coli derived cytosine deaminase c) Mammalian cytocrome P450
• the therapeutic polypeptide is TK.
• the therapeutic polypeptide is a viral antigen.
• viral antigen is selected from the group consisting of: a) Human Papilloma Virus derived oncoproteins E6 and E7 and derivatives thereof b) Human Hepatitis C derived NS3, NS5, El, E2, Core Antigen, and derivatives thereof c) HIV derived Tat and Env and derivative thereof
• the diagnostic polypeptide is a detectable moiety.
• an expression vector comprising the polynucleotide of the present invention.
• a viral particle comprising the protein or expression vector of the present invention. Also referred to herein as Nef 7-based VLP.
• the viral particle is derivable from a retrovirus or lentivirus, such as HIV or MLV.
• the viral particle is pseudotyped.
• the viral particle is pseudotyped with the viral envelope protein VSV-G, RDl 14 glycoprotein, MLV glycoprotein or a chimeric protein comprising the extracellular and transmembrane domains of RDl 14 and cytoplasmic domain of MLV glycoproteins.
• the viral particle is pseudotyped with HIV cell receptors.
• the viral particle is pseudotyped with CD4 and CXCR4 or with CD4 and CCR5 HIV cell receptors.
• the viral particle is pseudotyped with a tumor cell surface antigens.
• the viral particle is pseudotyped with a ligand of a tissue marker.
• a cell comprising the protein, the polynucleotide, the expression vector or the viral particle of the present invention.
• the cell is a host cell.
• the cell is a tumor cell.
• the cell is a dendritic cell, a lymphocyte or a monocyte.
• a method comprising exposing a cell obtainable from an individual to the protein or the viral particle of the present invention.
• a pharmaceutical composition comprising the protein, the cell or the viral particle of the present invention, together with a pharmaceutically acceptable carrier, excipient or diluent.
• the protein, the polynucleotide, the expression vector, the cell or the viral particle of the present invention for use in medicine.
• the protein, the polynucleotide, the expression vector, the cell or the viral particle of the present invention for the preparation of a medicament for the treatment of cancer.
• the protein, the polynucleotide, the expression vector, the cell or the viral particle of the present invention for the treatment of infectious diseases.
• Nef7-based VLPs may be a useful tool for example: i) as part of alternative protocols for gene therapy-based cell suicide strategies targeted to malignancies; ii) for the therapeutic targeting of infected cells;iii) in cancer vaccines and for the preparation of vaccines against infectious diseases and iv) for the targeting to specific cells and tissues of therapeutic or diagnostic polypeptide.
• VLPs can selectively recognize a cell target in which pathologic alterations lead to the expression on the cell membrane of specific markers. This can occur in tumors (e.g. melanoma-associated antigens) (26) as well as in infected cells. In the latter case, a therapeutic intervention could rely on the delivery of Nef7/fusion molecules by means of the "inverse" fusion between VLPs carrying the viral cell receptors, and the infected cells expressing the virus receptor.
• the use as immunogen of tumor antigens delivered by Nef7-based VLPs may have an advantage from the fact that, as previously demonstrated for HIV virions (21), they can recognize the so-called "cross- presentation" process, leading to the exposition in both Class I and Class II MHC.
• Nef7 -based VLPs can also be used for the preparation of vaccine against infectious diseases.
• the Nef7-based VLPs of the present invention can be regarded as a both reliable and versatile protein delivery system exploitable for a variety of experimental/therapeutic purposes for example, both human and murine systems.
• the present invention also relates to a novel anti-HIV therapeutic approach based on the recovery of anti-HIV- 1 Env targeted VLPs carrying a fusion protein of the present invention and expressing T- or M-specific HIV cell receptor complexes.
• Such VLPs deliver the fusion protein upon the "inverse fusion" process. In a therapeutic context this may ultimately lead to cell death.
• use may be made of a Nef/TK product in the presence GCV.
• Nef7-based VLPs efficiently enter cells infected by T- or M-tropic HIV-I strains, respectively.
• the delivery of the VLP-associated Nef7/TK correlated with the induction of cell death upon 5 to 7 days re-culture with GCV.
• VLPs were effective also against ex vivo, non-replicating human monocyte-derived macrophages infected by HIV-I in vitro.
• HIV-targeted VLPs may be used for the treatment of persistently HIV-I infected cells, that in AIDS patients represent virus reservoirs resistant to HAART therapies.
• Nef7 based VLPs can be targeted to specific cells and tissue with great efficiency. This system allows to deliver therapeutic or diagnostic polypeptide to a target cells or tissues.
• the present invention relates to a fusion protein, or conjugate, which is a molecule comprising at least one Nef7 protein linked to at least one heterologous polypeptide (or peptide or protein) such as may be formed through genetic fusion or chemical coupling.
• linked we mean that the first and second sequences are associated such that the second sequence is able to be transported by the first sequence in a viral vector.
• the fusion protein of the present invention includes proteins in which the Nef7 protein is linked to a heterologous polypeptide via their polypeptide backbones through genetic expression of a DNA molecule encoding these proteins, directly synthesised proteins and coupled proteins in which pre-formed sequences are associated by a cross-linking agent.
• the term is also used herein to include associations, such as aggregates, of the Nef7 with the heterologous polypeptide.
• the second sequence may comprise a polynucleotide sequence. This embodiment may be seen as a protein/nucleic acid complex.
• the second sequence is heterologous in the sense that it is different to the Nef7 protein.
• the second sequence may be from the same species as the first sequence.
• the Nef7 may be coupled directly to the heterologous polypeptide or indirectly through a spacer, which can be a single amino acid, an amino acid sequence or an organic residue.
• Nef is a myristoylated regulatory protein expressed by HIV- 1/2 and SIV having molecular weights of 27 and 34 kDa, respectively, and lacking any enzymatic activity (for reviews, see 30-32).
• the Nef N-terminal myristoylation ensures a preferential cell membrane localization, correlating with its virion incorporation occurring upon the viral protease-mediated cleavage at the amino acid positions 57-61 (depending on the allele considered) (33- 36).
• the biological significance of the Nef virion incorporation remains to be fully elucidated, even if recently it was suggested that virionic Nef is involved in the HIV penetration through the cortical actin network (37).
• Nef virion incorporation occurs mainly as the consequence of the disposition of Nef at the cell membrane, and more in particular at the "detergent resistant microdomains" (rafts) (38), from which HIV preferentially buds (39). This is consistent with the observation that Nef incorporates also in heterologous retroviruses, such as the Moloney Leukemia Virus (34).
• Nef7 By back-mutating the F12-Nef allele (32), we isolated a Nef mutant (Nef7) showing an efficiency of incorporation so high that it allows its use as a carrier molecule.
• Nef7 the V 153 L , E 177 G , here defined Nef7 and having the sequence shown in SEQ ID NO:1 having the unique property to undergo virion incorporation at quite high levels. This can occur whether Nef7 is expressed in cis or in trans with respect to the viral genome.
• wt wild-type Nef.
• wt HIV-I Nef incorporates in virions at low levels, i.e.
• Nef7 may be used with viral particles other than HIV since HIV -products are not required for the high incorporation of Nef7 into the virions.
• the Nef7 mutant is useful for both lenti- and retroviral particles, and indeed other types of viral particles.
• Nef7-based fusion products of the present invention has no major negative effects on viral particle assembling.
• Nef7-based fusion products are incorporated at high levels in empty virions. This is advantageous from a safety point of view.
• Nef7-based fusion products of the present invention may be used to efficiently kill both replicating and resting cells.
• VLPs Viral Particles or Viral Like Particles
• the Nef-7 mutant is able to transfer proteins using viral particles.
• the viral particles may be empty in the sense that they do not contain genetic material usually associated with viral particles, and are hence often referred to as viral like particles or VLPs.
• the VLPs of the present invention together with the use of the Nef7 mutant represent a new drug delivery system.
• This drug delivery system may be applicable in general for the delivery of a wide range of polypeptides, peptides and proteins.
• encapsidation into VLPs has the advantage that the protein of interest is protected inside a stable protein shell from external proteases. It is also possible to modify the surface of the VLP so as to allow targeting of specific cell types.
• different proteins of interest could be encapsidated and administered simultaneously with, for example, a defined ratio.
• the heterologous polypeptide of the present invention may be any polypeptide of interest, but is generally one which has a therapeutic effect or a potential therapeutic effect. By “therapeutic” we include diagnostic and preventative uses.
• the heterologous polypeptide may be obtainable from or produced by any suitable source, whether natural or not.
• the heterologous polypeptide may be designed or obtained from a library of peptides. It may be a peptidomimetic, a peptide cleaved from a whole protein, a peptide synthesised synthetically (such as, by way of example, either using a peptide synthesiser) or by recombinant techniques or combinations thereof. It may also be a peptide under test.
• polypeptide as used herein includes peptides and proteins.
• polypeptide includes single-chain polypeptide molecules as well as multiple- polypeptide complexes where individual constituent polypeptides are linked by covalent or non-covalent means.
• polypeptide sequences for use in the invention are not limited to the particular sequences or fragments thereof but also include homologous sequences obtained from any source, for example related viral/bacterial proteins, cellular homologues and synthetic peptides, as well as variants or derivatives thereof.
• Polypeptide sequences of the present invention also include polypeptides encoded by the polynucleotides of the present invention.
• Peptides of the present invention may be administered therapeutically to patients. It is preferred to use peptides that do not consisting solely of naturally-occurring amino acids but which have been modified, for example to reduce immunogenicity, to increase circulatory half-life in the body of the patient, to enhance bioavailability and/or to enhance efficacy and/or specificity.
• PEG polyethylene glycol
• PPG polypropylene glycol
• bifunctional crosslinkers such as N-succinimidyl 3-(2 pyridyldithio) propionate, succinimidyl 6- [3 -(2 pyridyldithio) propionamido] hexanoate, and sulfosuccinimidyl 6- [3 -(2 pyridyldithio) propionamidojhexanoate (see US Patent 5,580,853).
• bifunctional crosslinkers such as N-succinimidyl 3-(2 pyridyldithio) propionate, succinimidyl 6- [3 -(2 pyridyldithio) propionamido] hexanoate, and sulfosuccinimidyl 6- [3 -(2 pyridyldithio) propionamidojhexanoate.
• Conformational constraint refers to the stability and preferred conformation of the three-dimensional shape assumed by a peptide.
• Conformational constraints include local constraints, involving restricting the conformational mobility of a single residue in a peptide; regional constraints, involving restricting the conformational mobility of a group of residues, which residues may form some secondary structural unit; and global constraints, involving the entire peptide structure.
• the active conformation of the peptide may be stabilised by a covalent modification, such as cyclization or by incorporation of gamrna-lactam or other types of bridges.
• side chains can be cyclized to the backbone so as create a L-gamma- lactam moiety on each side of the interaction site.
• Cyclization also can be achieved, for example, by formation of cysteine bridges, coupling of amino and carboxy terminal groups of respective terminal amino acids, or coupling of the amino group of a Lys residue or a related homolog with a carboxy group of Asp, GIu or a related homolog.
• Coupling of the .alpha-amino group of a polypeptide with the epsilon-amino group of a lysine residue, using iodoacetic anhydride, can be also undertaken. See Wood and Wetzel, 1992, Int'l J. Peptide Protein Res. 39: 533-39.
• Another approach described in US 5,891,418 is to include a metal-ion complexing backbone in the peptide structure.
• the preferred metal-peptide backbone is based on the requisite number of particular coordinating groups required by the coordination sphere of a given complexing metal ion.
• most of the metal ions that may prove useful have a coordination number of four to six.
• the nature of the coordinating groups in the peptide chain includes nitrogen atoms with amine, amide, imidazole, or guanidino functionalities; sulfur atoms of thiols or disulfides; and oxygen atoms of hydroxy, phenolic, carbonyl, or carboxyl functionalities.
• the peptide chain or individual amino acids can be chemically altered to include a coordinating group, such as for example oxime, hydrazino, sulfhydryl, phosphate, cyano, pyridino, piperidino, or morpholino.
• a coordinating group such as for example oxime, hydrazino, sulfhydryl, phosphate, cyano, pyridino, piperidino, or morpholino.
• the peptide construct can be either linear or cyclic, however a linear construct is typically preferred.
• One example of a small linear peptide is Gly-Gly-Gly-Gly which has four nitrogens (an N 4 complexation system) in the back bone that can complex to a metal ion with a coordination number of four.
• a further technique for improving the properties of therapeutic peptides is to use non-peptide peptidomimetics.
• a wide variety of useful techniques may be used to elucidating the precise structure of a peptide. These techniques include amino acid sequencing, x-ray crystallography, mass spectroscopy, nuclear magnetic resonance spectroscopy, computer-assisted molecular modelling, peptide mapping, and combinations thereof.
• Structural analysis of a peptide generally provides a large body of data which comprise the amino acid sequence of the peptide as well as the three- dimensional positioning of its atomic components. From this information, non-peptide peptidomimetics may be designed that have the required chemical functionalities for therapeutic activity but are more stable, for example less susceptible to biological degradation. An example of this approach is provided in US 5,811,512.
• Retroviridae is a family of retroviruses that differs in nucleotide and amino acid sequence, genome structure, pathogenicity, and host range. This diversity provides opportunities to use viruses with different biological characteristics to develop different therapeutic applications. As with any delivery tool, the efficiency, the ability to target certain tissue or cell type, and the safety of retroviral-based systems are important. Significant efforts have been dedicated to these areas of research in recent years in relation to their use in gene therapy.
• VLPs of the present invention may be designed so that they do not contain viral genomic material, they are incapable of replication and hence represent a major advantage over the use of viral particles in a gene therapy context.
• viruses from several different families have been modified to generate viral vectors for gene delivery, and may also be used in the present invention. These viruses include retroviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, picornaviruses, and alphaviruses.
• the present invention preferably employs retroviruses, including lentiviruses.
• An ideal retroviral vector for gene delivery must be efficient, cell-specific, regulated, and safe. The efficiency of delivery is important because it can determine the efficacy of the therapy.
• Safety is a major issue for viral gene delivery because most viruses are either pathogens or have a pathogenic potential. It is important that during gene delivery, the patient does not also inadvertently receive a pathogenic virus that has full replication potential. As indicated above, the present invention avoids such problems in that the VLPs of the present invention lack the genomic material of the wild-type virus.
• Retroviruses are RNA viruses that replicate through an integrated DNA intermediate. Retroviral particles encapsidate two copies of the full-length viral RNA, each copy containing the complete genetic information needed for virus replication. Retroviruses possess a lipid envelope and use interactions between the virally encoded envelope protein that is embedded in the membrane and a cellular receptor to enter the host cells. Using the virally encoded enzyme reverse transcriptase, which is present in the virion, viral RNA is reverse transcribed into a DNA copy. This DNA copy is integrated into the host genome by integrase, another virally encoded enzyme. The integrated viral DNA is referred to as a provirus and becomes a permanent part of the host genome. The cellular transcriptional and translational machinery carries out expression of the viral genes.
• the host RNA polymerase II transcribes the provirus to generate RNA, and other cellular processes modify and transport the RNA out of the nucleus.
• a fraction of viral RNAs are spliced to allow expression of some genes whereas other viral RNAs remain full-length.
• the host translational machinery synthesizes and modifies the viral proteins.
• the newly synthesized viral proteins and the newly synthesized full-length viral RNAs are assembled together to form new viruses that bud out of the host cells.
• this viral RNA which has the ability to be reverse transcribed and subsequently integrated in the host genome is omitted from the VLP.
• retroviruses can be classified into simple and complex retroviruses. Simple and complex retroviruses encode gag (group-specific antigen), pro (protease), pol (polymerase), and env (envelope) genes. In addition to these genes, complex retroviruses also encode several accessory genes. These may be removed, if appropriate, in the present VLPs. Retroviruses can also be classified into oncoviruses, lentiviruses, and spumaviruses. Most oncoviruses are simple retroviruses. Lentiviruses, spumaviruses, and some oncoviruses are complex retroviruses. Currently, all three types of viruses are being exploited as gene therapy tools and may be used in the present VLPs. Examples of each type will be discussed below.
• Murine leukemia virus is example of an oncovirus
• human immunodeficiency virus 1 HIV-I
• human foamy virus is an example of a spumavirus.
• a replication-competent retrovirus When a replication-competent retrovirus infects a natural host cell, it can form a provirus in the host genome, express viral genes, and release new infectious particles to infect other hosts. In most gene therapy applications, it is not desirable to deliver a replication-competent virus into a patient because the virus may spread beyond the targeted tissue and cause adverse pathogenic effects. Therefore, in most retroviral systems designed for gene delivery, the viral components are divided into a vector and a helper construct to limit the ability of the virus to replicate freely.
• vector generally refers to a modified virus that contains the gene(s) of interest and cis-acting elements needed for gene expression and replication. In the present invention this is replaced by the Nef7 fusion protein of the present invention.
• Helper cells are engineered culture cells expressing viral proteins needed to propagate retroviral vectors; this is generally achieved by transfecting plasmids expressing viral proteins into culture cells. Most helper cell lines are derived from cell clones to ensure uniformity in supporting retroviral vector replication. Helper viruses are not used often because of the likelihood that a replication-competent virus could be generated through high frequency recombination. Helper functions can also be provided by transient transfection of helper constructs to achieve rapid propagation of the retroviral vectors.
• retroviral vectors are maintained as bacterial plasmids to facilitate the manipulation and propagation of the vector DNA.
• These double-stranded DNA vectors can be introduced into helper cells by conventional methods such as DNA transfection, lipofection, or electroporation.
• the helper cell expresses all of the viral proteins (Gag, Gag-Pol, and Env) but lacks RNA containing the packaging signal.
• viral RNA is necessary for the formation and release of infectious viral particles, but it is not necessary for the formation of "empty" noninfectious viral particles.
• the viral particles contain viral proteins expressed from helper constructs and the Nef7 fusion protein of the present invention.
• the Nef7 fusion protein of the present invention is expressed from an expression vector which has been incorporated into the helper cell. These viral particles can infect target cells, and deliver the protein of interest to the target cell. However, because the vector does not express any viral proteins, it cannot generate infectious viral particles that can spread to other target cells.
• Helper cells are designed to support the propagation of retroviral vectors.
• the viral proteins in the helper cells are expressed from helper constructs that are transfected into mammalian cells. Helper constructs vary in their mode of expression and in the genes they encode.
• helper cell lines using "split genomes", including CRIP, GP+envAml2, and DSN.
• the viral Gag/Gag-Pol polyproteins are expressed from one plasmid and the Env proteins are expressed from another plasmid.
• Use may be made of such constructs in the present invention. These are particularly useful when a pseudotyped VLP is being prepared.
• helper cell lines In contrast to the helper cell lines described above that express viral proteins constitutively, some helper cell lines have been designed to express the viral proteins in an inducible manner.
• One rationale for the generation of an inducible helper cell line is that some viral proteins are cytotoxic and cannot be easily expressed at high levels. By using an inducible system, expression of the cytotoxic proteins can be limited to the stage in which virus is propagated. By controlling the expression of the cytotoxic proteins, high viral titers can be achieved. Examples of the inducible helper cells include the 293 GPG cells and HIV-I helper cell lines.
• transient transfection systems have also been developed for propagation of retroviral vectors.
• helper functions are generally expressed from two different constructs, one expressing gag-pol and another expressing env. These two constructs generally share little sequence homology.
• the retroviral vector and the helper constructs are transfected into cells, and viruses are harvested a few days after transfection.
• Pseudotyping refers to viral particles containing a viral genome from one virus and part (or all) of the viral proteins from a different virus.
• the most common form of pseudotyping involves one virus using the envelope protein of another virus.
• Some of the helper cell lines contain helper constructs that express gag-pol from one virus and env from another virus. Since the Gag polyproteins select the viral RNA, the viral vector to be propagated contains an RNA that is recognized by the Gag polyprotein expressed in these cells. However, the viral particles produced contain the Env protein derived from another virus. Therefore, these viral particles can only infect cells that express a receptor that can interact with the heterologous envelope protein.
• the helper cell line PGl 3 expresses gag-pol from MLV and env from gibbon ape leukemia virus (GaLV). Because the PGl 3 cell line expresses MLV Gag polyprotein, it can efficiently package MLV-based retroviral vectors. It has also been shown that some envelopes derived from viruses of a different family can also pseudotype retroviruses and generate infectious viral particles. For example, the G protein of vesicular stomatitis virus (VSV), a rhabdovirus, can be used to generate pseudotyped retroviral vectors. These VSV G pseudotyped viruses exhibit a very broad host range and can infect a variety of cells that cannot normally be infected with retroviruses.
• VSV vesicular stomatitis virus
• Pseudotyping may involve for example a retroviral genome based on a lentivirus such as an HIV or equine infectious anaemia virus (EIAV) and the envelope protein may for example be the amphotropic envelope protein designated 4070A.
• envelope protein may be a protein from another virus such as an Influenza haemagglutinin.
• the envelope protein may be a modified envelope protein such as a mutant or engineered envelope protein. Modifications may be made or selected to introduce targeting ability or to reduce toxicity or for another purpose.
• the viral particle can be pseudotyped with a chimeric glycoprotein comprising the extracellular and the transmenbrane domains derived from the glycoprotein of the feline endogenous virus RDl 14 and the cytoplasmic domain of the glycoprotein derived from MLV-A (WO03091442)
• the viral particle may express T- or M-specific HIV cell receptor complexes.
• the viral particle may incorporate CD4 and CXCR4 or CCR5 in their envelope.
• Oncoviruses Vectors Derived from Oncoviruses
• Oncoviruses can only infect dividing cells; therefore, vectors that are derived from oncoviruses can only be used to efficiently deliver genes into dividing cells.
• the requirement for cell proliferation can sometimes be used as an advantage to selectively target rapidly dividing cells (for example, cancer cells).
• protein delivery through the use of VLPs is independent of the cell replication even if the VLP derives from an oncoretrovirus. This is an additional advantage of the present invention.
• MLV -based retroviral vectors and helper cells are the most frequently used system for gene delivery.
• the development and availability of engineered vectors and helper cell lines has promoted the popularity of MLV-based vectors and they may be effectively used in the present invention.
• MLV-based vectors can be propagated in all of the MLV helper cell lines efficiently.
• MLV envelope proteins that dictate the host range of MLV vectors.
• Viruses that use the ecotropic envelope can infect mouse cells but not cells derived from other species.
• Viruses that use the amphotropic envelope can infect both mouse cells and cells derived from other species, including human cells.
• Viruses that use the xenotropic envelope cannot infect mouse cells but can infect cells derived from other species.
• MLV vectors can also be propagated in spleen necrosis virus (SNV)-based helper cell lines.
• SNV is an avian virus that is distantly related to MLV.
• SNV-based vectors can be propagated in SNV-based helper cell lines such as C3A2, DSDH, DSH134G, and DSN.
• RSV Rous Sarcoma Virus- and Avian Leukosis Virus-Based Vectors.
• RSV is the onlyknown acute oncogenic retrovirus that is replication-competent.
• ALV has also been modified to generate vectors that require helper cells for their propagation.
• Lentiviruses In contrast to the oncoviruses, some lentiviruses have been shown to infect nondividing, quiescent cells. Lentiviruses are complex retroviruses. As examples of lentivirus-based vectors, HIV-I- and HIV-2 -based vectors are commonly used.
• Foamy viruses are unconventional retroviruses in that many features in their replication cycle are different from those of oncoviruses and lentiviruses. Although these viruses can be toxic to cultured cells, none of the foamy viruses are known to cause any disease in hosts.
• An important goal for gene therapists is to develop a means to target gene delivery to specific cell types or tissues.
• At least two strategies have been used in an effort to target gene delivery using retroviral vectors.
• One strategy is designed to control gene delivery at the point of virus entry into the host cell by using natural or genetically engineered envelope proteins that interact with cell-type-specific receptors.
• Another strategy is designed to control expression of the therapeutic gene in specific cell types by using tissue-specific promoters.
• the nature of the viral envelope protein determines whether a certain virus can enter a target cell. Therefore, it is important to consider whether the target cells have the correct cell surface receptor before the selection of an envelope protein that will be used for virus production (as discussed above).
• diseases that are amenable to protein therapy include a variety of cancers, heart attacks, strokes, cystic fibrosis, Gaucher's disease, diabetes, anaemia and haemophilia and graft-versus-host disease after bone marrow transplantation.
• the direct introduction of proteins into cells may be useful to a variety of fields including cell cycle regulation, control of apoptosis, oncogenesis and transcription regustion.
• Several different therapy strategies may be used to treat a variety of cancers. These strategies include elimination of cancer cells by suicide therapy, reversion of cancer cells to normal cells by delivery of a functional tumor suppressor protein, and modification of cancer cells to elicit stronger immune responses.
• HSV-tk herpes simplex virus thymidine kinase enzyme
• GCV herpes simplex virus thymidine kinase enzyme
• the present invention allow to deliver therapeutic proteins specifically to HIV-I infected cells.
• these treatments have involved modification of the syngeneic lymphocytes ex vivo using retroviral vectors and are designed to suppress the expression of viral genes.
• Cytotoxic proteins have involved modification of the syngeneic lymphocytes ex vivo using retroviral vectors and are designed to suppress the expression of viral genes.
• the Nef7 mutant may be associated with such proteins, and used as a delivery tool for introducing the protein into a VLP.
• the protein is an anti- cancer agent.
• suicide therapy involves the transfer of enzymes that convert non-toxic pro-drugs into toxic antimetabolites. Examples of such enzyme are
• E.coli cytosine deaminase TK and the mammalian cytochrome P450 (CYP2B1), which confer sensitivity to 5-fluorocytosine, GCV and cyclophosphamide (CPA), respectively.
• the present invention may employ any such pro-drug; although in a preferred embodiment of the present invention use is made of TK.
• Dendritic cell (DC)-based vaccines are being developed for treatment of patients with cancer, in part because DCs are potent inducers of CD8+ CTL.
• DC MHC class Lantigenic peptide complexes that are required for CTL elicitation are most often generated by incubating DCs with peptides or by transfecting (or transducing) DCs with cDNAs or viral vectors that encode protein antigens.
• the use of viral vectors may be hampered by the preparation of such viral vectors.
• the present invention allows for the efficient delivery of the tumor antigen by the VLP directly to the target cell. Any useful tumor antigen, e.g. the SV40 large T antigen, may be employed in the present invention. Table A shows a list of known tumor antigens which could be used in the present invention. Table A
• HIV can either lead to cell death, mostly in activated CD4 lymphocytes, or establish a persistent infection in cells controlling the extent of HIV expression and resisting its cytopathic effect, such as macrophages and follicular dendritic cells.
• HIV can generate a latent infection in the case the viral genome remains silent upon integration in the host DNA.
• Latently infected cells could be induced to express HIV by the treatment with cytokines such as IL-2, anti-CD3, ⁇ lFN, or TNF ⁇ (for a review, see (41)), or with drugs, like prostratin (42, 43, 44) or 12-deoxyphorbol- 13 acetate (45), leading to cell activation in the absence of cell replication.
• HIV Env molecules undergo cell membrane exposition, thus rendering the infected cells readily and specifically recognizable by viral particles carrying the respective cell receptor complex.
• Nef7 -based VLPs carrying the viral cell receptor complexes enter HIV-I infected cells thereby, for example in an embodiment using Nef7/TK VLPs, inducing cell killing in both replicating and resting HIV-I infected cells cultured with GCV.
• the VLPs of the present invention comprising a Nef7 fusion product of the present invention provide new therapeutic tools against HIV infected cells, particularly those with longer half-life.
• the present invention has a therapeutic relevance even during the HAART treatment.
• the present invention allows for new VLP -based therapeutic strategies, and in particular for targeting persistently HIV infected cells such as monocyte/macrophages, follicular dendritic cells, and resting T lymphocytes.
• the treatment may impact also against latently infected T lymphocytes in the case the HIV expression is pharmacologically induced.
• HSV/TK-derived enzymes with stronger activity 46, 47, 48
• nucleosides analogues with shorter time of action may be made of HSV/TK-derived enzymes with stronger activity (46, 47, 48), and/or nucleosides analogues with shorter time of action.
• VLP infectivity in vivo in another embodiment use may be made of VLPs comprising the Nef7 fusion based product of the present invention, and in particular Nef7/TK- based VLPs, incorporating a VSV-G deletion mutant ("G stem") that has been demonstrated to relieve the CXCR4 or CCR5 requirement for CD4-dependent HIV-I
• G stem incorporating VLPs may be equally effective against cells infected by T- or M-tropic HIV isolates.
• Nef7 is incorporated at high levels in VLPs such as Simian Immunodeficiency Virus and Moloney Leukemia Virus viral particles, therefore, the VLPs of the present invention may be employed for both experimental and pre-clinical tests of new peptidic drugs in primates as well as in rodents.
• VLPs such as Simian Immunodeficiency Virus and Moloney Leukemia Virus viral particles
• the VLPs of the present invention may be employed for both experimental and pre-clinical tests of new peptidic drugs in primates as well as in rodents.
• Nef7 associated with a reporter gene for example Nef7/GFP, may be used as a reporter/fluorescent HIV-I particle for the study of the mechanisms underlying inverse fusion.
• the treatment protocol may involve an ex vivo approach involving removing the target cells from the patients, delivering the protein product/polypeptide of interest ex vivo, and putting the cells back into the patients.
• Nef7-based VLPs as vaccines for infectious diseases
• HPV/HCV therapeutic vaccine should efficiently stimulate the immune system to raise an effective and long-lasting humoral and cellular response.
• DCs Dendritic cells
• DCs loaded with antigens such as tumor associated antigen, are used to study the response of the different antigens and also as a vaccine in vivo.
• most DC vaccines have been used particularly to stimulate immune response against cancer.
• a promising vaccine delivery vehicle is represented by the virus-like particles.
• both DCs and Langerhans cells are able to cross-present HPV- like particles-associated antigen to CD8+.
• recent studies have shown that the adoptive transfer of autologous DCs loaded in vitro with inactivated HIV-I induced protective antiviral immunity in hu-PBL-SCID mice.
• VLPs containing high levels of HPV/HCV products fused to Nef7 MAY act as a vaccine by means of the internalization into DCs leading to the induction of an effective immune response selectively destroying infected cells.
• the viral antigen may be presented in both Class I and Class II MHC, thus eliciting a potent immunologic response;
• the antigens may be presented to the DC proteasome machinery in a rather natural conformation, thus guaranteeing a relevant immunologic response.
• Nef7-based VLP can be used for diagnostic purposes by pseudotyping the virion with an envelope protein able to interact with a specific cell or tissue and by associating Nef7 to a detectable moiety.
• detectable moiety refers to, a polypeptide having the property of rendering its presence detectable.
• a polypeptide labelled with a radioactive isotope which permits cells or the tissue in which VLP is present to be detected in immunohistochemical assays.
• a detectable moiety is a polypeptide detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means.
• the polypeptide can be labelled with radioisotopes (e.
• detectable polypeptide can be linked to fluorescent dyes, electron-dense reagents, biotin, digoxigenin, or haptens.
• detectable polypeptide are enzymes such as alkaline phosphatase, horseradish peroxidase, or others commonly used in an ELISA.
• Polynucleotides of the invention can be incorporated into a recombinant replicable vector.
• the vector may be used to replicate the nucleic acid in a compatible host cell.
• the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector.
• the vector may be recovered from the host cell.
• Suitable host cells include bacteria such as E. coli, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.
• a polynucleotide of the invention in a vector is operably linked to a control sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector.
• operably linked means that the components described are in a relationship permitting them to function in their intended manner.
• a regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.
• control sequences may be modified, for example by the addition of further transcriptional regulatory elements to make the level of transcription directed by the control sequences more responsive to transcriptional modulators.
• Vectors of the invention may be transformed or transfected into a suitable host cell as described below to provide for expression of a protein of the invention. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the protein, and optionally recovering the expressed protein.
• the vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter.
• the vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used, for example, to transfect or transform a host cell.
• Control sequences operably linked to sequences encoding the protein of the invention include promoters/enhancers and other expression regulation signals. These control sequences may be selected to be compatible with the host cell for which the expression vector is designed to be used in.
• promoter is well-known in the art and encompasses nucleic acid regions ranging in size and complexity from minimal promoters to promoters including upstream elements and enhancers.
• Vectors/polynucleotides of the invention may introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation and electroporation. Where vectors/polynucleotides of the invention are to be administered to animals, several techniques are known in the art. In the present invention use is preferably made of VLPs as discussed above.
• the present invention may involve an ex vivo approach in which modified cells are (re-)introduced into a patient or an in vivo or direct transfer approach in which the VLPs are used to deliver the heterologous polypeptides directly into the body of a patient.
• the composition of the invention may be introduced by direct injection.
• the composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular, oral or transdermal administration.
• each protein of interest may be administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.
• the substance of the invention is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition.
• suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline.
• the composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.
• the cells which are infected with the VLP of the present invention will be returned to the same patient.
• examples of cells include HIV-permissible cells, tumor cells, lymphocytes, monocytes, stem cells, dendritic cells and bone marrow cells. It will be appreciated that a cell type appropriate for the treatment may be selected.
• FIG. 1 Nef7 is strongly and specifically incorporated in both lenti- and retroviral particles.
• A Western blot analysis for the expression and virion incorporation of Nef7 expressed either in cis (top) or in trans (bottom).
• 293T cells were transfected with HIV-I NL4-3 molecular clones expressing either wt Nef or the Nef7 mutant, or, as control, with the isoform defective for the nef expression ( ⁇ nef).
• ⁇ nef isoform defective for the nef expression
• cells were transfected with the ⁇ «e/NL4-3 alone or with vectors expressing either wt Nef or Nef7. In both cases, non-transfected cells (Ctrl) were used as control.
• 293T cells were transfected with a molecular clone expressing the whole MLV genome together with vectors expressing either wt or Nef7. Non-transfected cells were used as control (Ctrl). Forty-eight hours thereafter, both cells and supernatants were harvested for the Western blot analysis. Thirty ⁇ g of cell lysates were analyzed for the expression of both Nef and actin, and, at the same time, supernatants were concentrated, viral contents measured by RT assay. The amounts equivalent to 5x10 6 cpm of MLV particles were run and analyzed for the presence of virionic Nef by incubating the filters with anti-Nef polyclonal Abs.
• Nef7 accumulates in rafts at high levels.
• Western blot analysis of fractions recovered from discontinuous sucrose gradients carried out on lysates from 5x10 293T cells transfected with NL4-3 or NL4-3/Nef7 HIV-I molecular clones, or with ⁇ nef NL4-3 together with wt Nef or Nef7 expressing vectors.
• Forty-height hours after transfection cells were lysed, 50 ⁇ g of total proteins analyzed for the Nef expression (A), and the remainder cell lysates run in 4 ml gradients.
• FIG. 3 Nef7-based fusion products are incorporated at high efficiency in HIV-I VLPs.
• 293T cells were co-transfected with the HIV-I packaging construct pCMV ⁇ R8.74 and a vector expressing the VSV-G receptor in the absence (Ctrl) or in the presence of vectors expressing the diverse Nef derivatives. Forty-eight hours after, supernatants were harvested, clarified, concentrated and titrated. Volumes equivalent to 20 ng of each viral preparation were then loaded in 10% SDS-PAGE and analyzed by Western blot for the presence of Nef and p24 Gag-related products. Abs preparations used were quoted in the legend of Fig. IA
• FIG. 4 Nef7/GFP is efficiently delivered in cells by VLPs.
• A Effective removing of adsorbed VLPs by trypsin treatment. Ten ng of (VSV-G) Nef7/GFP VLPs were used to challenge 10 5 CEMss cells for 2 hours at 4 °C. Then, cells were treated or not with trypsin for 10 minutes at 4 0 C, and analyzed by FACs for the GFP-related fluorescence.
• B Delivery of Nef7/GFP molecules upon VLP challenge. Ten ng of Nef7/GFP VLPs expressing or not the VSV-G receptors were used to infect 10 5 CEMss cells.
• FIG. 5 Cell killing upon (VSV-G) Nef7/TK VLP challenge of CEMss cells and GCV cultivation. Growth kinetics of CEMss cells left untreated or challenged with VSV-G pseudotyped Nef7 or Nef/TK VLPs 5 and cultivated in the presence or absence of GCV. Twenty ng of VLPs were adsorbed to 10 5 cells for two cycles of two hours at 37 °C.
• FIG. 6 Primary human MDM cells are efficiently killed by (VSV-G)Nef7/TK VLPs. Cell viability as evaluated by FACs scatter plot analysis of MDM from two healthy donors (I-II) after challenge with 1 to 5 ng of (VSV-G) Nef7/TK VLPs and cultivation in the presence or not of GCV. As control, cells either unchallenged or challenged with Nef7 (VSV-G) VLPs and cultivated with or without GCV, were also analyzed.
• 2x10 5 MDM were challenged in 48-well plates by adsorbing increasing doses of (VSV-G) Nef7/TK VLPs in 100 ⁇ l of complete medium at 37°C, and then cultivated in 300 m,l of complete medium in the presence or not of GCV. Cells from replicated wells were then collected daily and analyzed for the cell viability. Data refer to the analysis performed at the day 5 after challenging on MDM from six healthy donors.
• FIG. 7 The challenge with (VSV-G) Nef7/TK VLPs induces an increase of Annexin-V binding in both replicating and resting cells.
• CEMss cells and MDM were infected by (VSV-G) Nef7/TK VLP as above described, and cultivated with or without GCV. From 2 till 5 days for CEMss cells, or three days after the challenging for MDM, cells were harvested, labelled with FITC-conjugated Annexin-V and PI, and analyzed by FACs.
• FIG. 8 The (VSV-G)Nef7/TK VLP challenge induces the decrease of the levels of intracytoplasmic Bcl-2.
• Nef7/TK VLPs were cultivated in the presence or in the absence of GCV.
• cell cultures either unchallenged (Ctrl) or challenged with (VSV-G)Nef7
• VLPs and maintained in GCV are included.
• CEMss cells were challenged by VLPs as described in the legend of Fig. 5 and, from 2 to 4 days thereafter, were labelled with a
• FIG. 9 Molecular analysis of Nef7 -based VLPs. Western blot analysis of different Nef7-based VLPs. 293T cells were co-transfected with the HIV-I packaging construct pCMV ⁇ R8.74 together with vectors expressing either CD4T, CXCR4 or
• Nef7-GFP is efficiently delivered in cells by both (CD4-CXCR4) and (CD4-CCR5) VLPs.
• Both cell cultures were preliminarly analyzed by FACs for the membrane expression of HIV-I gpl20 using a 1:100 dilution of the 4G10 anti-gpl20 mAb or the same amounts of isotype-matched, specie-specific IgG as control.
• Nef7/GFP (CD4-CXCR4) or (CD4-CCR5) VLPs were used to infect 10 5 of either 8E5 cells or 293T cells 48 hours after the transfection with ADA HIV-I molecular clone, respectively.
• the same amounts of Nef7/GFP VLPs expressing CD4 alone were used. After extensive washings, cells were incubated at 37 0 C in complete medium and, after 3, 6 and 10 hours, harvested, incubated 5 minutes with trypsin, and analyzed by FACs for the GFP -related fluorescence. The percentages of GFP positive cells are indicated in the respective quadrants.
• FIG. 11 T-tro ⁇ ic HIV-I chronically infected cells are killed upon (CD4-CXCR4) Nef7/TK VLP challenge and GCV treatment. Cell viability expressed as percentages of untreated cells, measured in 8E5 cells seven days after the challenge with Nef/TK
• VLPs pseudotyped by VSV-G or CD4-CXCR4 receptors, and treated or not with
• GCV 10 5 cells were spinoculated with 50 ng of VLPs for three cycles and, thereafter, seeded in complete medium in the presence or not of 10 ⁇ M GCV. After seven days, the cell viability was scored by the trypandian exclusion dye. As control, mockinfected 8E5 cells cultivated in the presence of GCV were included (Ctrl). The means values ⁇ sd from seven independent experiments are reported.
• FIG. 12 Selective elimination of human T cells acutely infected with T-tropic HIV- 1 upon challenging with (CD4-CXCR4) Nef7/TK VLPs. Percentages of fluorescent cells as scored by FACs analysis of CEM-GFP cells infected with increasing doses of T-tropic HIV-I and challenged with (CD4-CXCR4) Nef7/TK VLPs. CEM-GFP cells were infected with 2 to 50 ng of NL4-3 HIV- 1/10 5 cells by adsorbing the viral inoculum in 50 ⁇ l for 2 hours at 37 °C. Thereafter, cells were kept in culture for two days and then challenged with 30 ng of VLPs /10 5 cells for two cycles. Finally, cells were re-fed in complete medium in the presence or in the absence of GCV, and monitored for the GFP -associated fluorescence after additional five days. Results are the means values from two independent experiments.
• FIG. 13 Blocking of viral spread upon challenge with (CD4-CCR5) Nef7/TK VLPs of MDM acutely infected with M-tropic HIV-I.
• HIV-I amounts measured as ng/ml of p24 Gag HIV-I in supernatants harvested at the indicated days after the infection of MDM with 100 pg/10 5 cells of ADA HIV-I followed, two days after, by two cycles of challenge with 30 ng/10 5 cells of (CD4-CCR5) Nef7/TK VLPs, and cultivation in the presence or absence of GCV.
• Data are representative of independent experiments performed on MDM from three healthy donors.
• FIG. 14 Selective elimination of HIV-I expressing MDM upon challenge with (CD4-CCR5) Nef7/TK VLPs. 10 5 five days-old MDM were infected with 1 ng of
• VSV-G HIV-I or left untreated (Ctrl).
• infected MDM were challenged or not with 50 ng/10 5 cells of (CD4-CCR5) Nef7/TK VLPs for three cycles, and cultivated in the presence or absence of GCV.
• the percentages of HIV-I Gag expressing cells were evaluated by FACs analyses. Percentages of positive cells are reported in the respective panels. Data are representative of the analysis performed on MDM from two healthy donors.
• FIG. 15 Sequence ID No: 1.
• FIG. 16 CD8+ MAGE-3 specific T cells were cultured with autologous DCs previously infected with HIV VLPs (Nef7/MAGE-3 VSV-G and Nef7/MAGE-3 RDl 14) and with MLV-VLP (Nef7/MAGE-3). The presence of IFN- ⁇ in the supernatant was measured by ELISA after 24 hours.
• Vectors expressing the NL4-3 HIV-I (52) and its derivatives, i.e. the viral genomes deleted of the ⁇ e/gene ( ⁇ e/HIV-1) (53), and expressing the Nef7 mutant (54) have been already described.
• the pCMV ⁇ R8.74 plasmid (55) was used as HIV-I packaging construct.
• VSVG, wt Nef and Nef7 were expressed under the control of the immediate-early cytomegalovirus (ie-CMV) promoter.
• the construction of vector expressing the Nef7-GFP fusion protein was already described (45).
• the open reading frame encoding the Nef7/TK fusion protein was obtained through the overlapping polymerase chain reaction (PCR) procedure.
• Nef7 and HSV-TK genes were amplified from, respectively, pcDNA3-Nef7 and TgCMV-Hy/TK expressing vectors, using DyNAzyme EXT polymerase (Finnzymes, Espoo, Finland).
• oligoprimers are the following: Nef7 Forward:5' GCG AAG CTT ATG GGT GGC AAG TGG TCA AAA 3'; Nef7 Reverse: 5' CTG GTC GAA CGC AGA CGC GCA GTT CTT GAA GTA CTC CGG 3'; TK Forward: 5' GAG TAC TTC AAG AAC TGC GCG TCT GCG TTC GAC CAG GCT 3'; TK Reverse: 5' CGC GGA TCC TCA GTT AGC CTC CCC CAT CTC 3'. Both cloning sites (i.e., Hind III and Bam HT) and overlapping sequences are underscored.
• the stop codon was removed in the Nef7 sequence, and the TK gene started with an Alanine residue.
• Single PCR products were purified from agarose gel, and mixed in a single PCR amplification (100 ng each in 50 ⁇ L of final reaction volume) using exclusively the Nef7 Forward and the TK Reverse as primers.
• the final amplification product was purified, doubly digested with Hind III and Bam Hl restriction sites, and inserted in the homologous sites of the pcDNA3 vector.
• AU PCR products were sequenced by the dideoxy chain termination method.
• PBMC peripheral blood mononucleated cells
• Lymphocytes were negatively selected from PBMC using the appropriate immunomagnetic-based selection kit from Miltenyi Bioytec (Auburn, CA).
• PBLs were activated with 2 ⁇ g/ml phytohemagglutinin (Sigma-Aldrich, Milan, Italy), and cultivated in RPMI containing 20% of dFCS in the presence of 100 U/ml of recombinant human IL-2 (Roche, Nutley, NJ).
• Monocytes were isolated by 1 h adherence of PBMC, followed by immunomagnetic depletion of non-monocytic cells carried out through a Miltenyi selection kit. Monocytes were cultivated in 48-well plates in RPMI supplemented with 20% of dFCS.
• Ganciclovir was from Synthex Laboratories, Inc. (Palo Alto, CA) and was used at the concentration of 10 to 30 ⁇ M.
• VLP production, titration, and challenges Preparations of VSV-G pseudotyped VLPs were obtained from supernatants of 293T cells 48-60 h after the calcium phosphate co-transfection with the pCMV ⁇ R8.74 packaging vector (55), the Nef7 or Nef7 -based fusion products expressing vectors, and a plasmid expressing the VSV-G, in a molar ratio of 3:3:1. Supernatants were clarified and concentrated by ultracentrifugation as described (56). In some instances, the concentrated VLPs were purified through additional ultracentrifugation (SW 60 rotor, 30,000 g, 4h at 4°C) by loading the concentrated viral particles on a 20% sucrose cushion.
• SW 60 rotor 30,000 g, 4h at 4°C
• VLP preparations were titrated both by measuring HIV-I p24 contents by quantitative ELISA (Abbott, Abbott Park, Illinois), and by the reverse transcriptase assay (56). VLPs were adsorbed incubating the cells for 1 h at 37 0 C. Afterwards, the cells were re-fed by adding fresh medium complemented or not with GCV. In the case of Nef7- GFP VLP infections, cells underwent spinoculation, i.e., the adsorption of VLPs to cells by means of 1 h of centrifugation at 150 g at r.t. Afterwards, the cells were washed to eliminate non adsorbed VLPs, re-fed by adding fresh medium, collected at different times, treated for 5 min with trypsin at r.t., and finally analyzed by FACs.
• spinoculation i.e., the adsorption of VLPs to cells by means of 1 h of centrifugation at 150 g at r.t
• the evaluation of cell mortality was performed either by labeling cells with the trypan blue exclusion dye, by analyzing the scatter profile by FACs (FACscalibur, Becton- Dickinson, Mountain View, CA), and by scoring the labeled cells by FACs after the treatment with 5 ⁇ g/ml of propidium iodide (PI).
• FACscalibur Becton- Dickinson, Mountain View, CA
• PI propidium iodide
• the pulse-chase labeling assay was performed by transfecting 293T cells with vectors expressing either wt Nef or Nef7 alone or in the presence of ⁇ nef HIV-I expressing vector, and, 48 h thereafter, labeling the cells with 1,85 MBq/ml of both 35 S-cysteine and -methionine in cysteine/methionine free medium for 4 h in the presence of 10% dialyzed dFCS. Cells were then extensively washed, and re-seeded in complete medium.
• Plasma membrane rafts were obtained essentially as previously described (57). Briefly, transfected 293T cells were washed with ice-cold phosphate-buffered saline (PBS) and lysed at 4°C in a buffer containing 25 mM morpholineethanesulfonic acid (pH 6.5), 1% vol/vol Triton X-100, and protease inhibitors. The cell lysates were then homogenized and adjusted to 40% sucrose.
• PBS ice-cold phosphate-buffered saline
• a discontinuous sucrose gradient (40%-35%-5%) was then loaded on the cell lysate, and the sample ultra-centrifuged at equilibrium for 18 h at 4°C, 200,000 g, SW 60 rotor on a Beckman L70-ultracentrifuge. From the top of the gradient, 0.35 ml fractions were collected to yield a total of 12 fractions. Proteins from each fraction were finally quantified through the Bio-Rad assay (Bio-Rad, Hercules, CA), separated by 10% SDS-PAGE, and subjected to immunoblot analysis.
• Annexin-V binding assays were performed by re- suspending cells in binding buffer (100 niM Hepes, 140 mM NaCl, 5 mM CaCl 2 , pH 7.4), and adding 1:20 diluted of FITC-conjugated Annexin-V (BD Biosciences, Mountain View, CA) for 30 min at r.t. Thereafter, 5 ⁇ g/ml of PI was added, and, after additional 5 min, cells were analyzed by FACs.
• binding buffer 100 niM Hepes, 140 mM NaCl, 5 mM CaCl 2 , pH 7.4
• FITC-conjugated Annexin-V BD Biosciences, Mountain View, CA
• Nef7 a Nef double mutant (the V 153 L , E 177 G , here defined Nef7) having the unique property to undergo virion incorporation at quite high levels. As shown in Fig.
• Nef7 virion incorporation compared with wt Nef (not shown). This was not the consequence of differences in the antibody recognition, as similar results were obtained using different either mono- or polyclonal anti-Nef antibody preparations
• Nef7 mutant is incorporated at unusually high levels in VLPs such as lenti- and retroviral particles.
• rafts detergent-resistant microdomains
• rt Nef or Nef7 were expressed by transfecting 293T cells as part of the HIV-I genome or together with a vector expressing the ⁇ nef HIV-I genome. Forty-eight h thereafter, cells were lysed, tested for the Nef expression (Fig.
• Nef7 was reproducibly found in rafts at higher levels in comparison to wt Nef.
• Nef7 alone was not shown, indicating that its accumulation in rafts does not require the presence of additional HIV-I products. This may account for the highly efficient incorporation of Nef7 also in MLV, a murine retrovirus assembling at the lipid rafts as well (55).
• Nef7 virion incorporation could be exploited as a new system of protein delivery.
• Both Nef7/GFP and Nef7/TK VLPs were recovered upon concentration of supernatants of 293T cells co- transfected with the pCMV ⁇ R8.74 HIV-I packaging construct (55), a VSV-G expressing vector, and the vectors expressing the respective Nef-derivative.
• Nef7/GFP Fig. 3A
• Nef7/TK Fig. 3B
• VLF '-Associated Nef7 is Efficiently Delivered into the Cells
• Nef7-based fusion products undergo internalization in VLP-challenged cells.
• 10 ng of (VSV-G) Nef7/GFP or, as control, Nef7-GFP VLPs deprived of receptors ("null" VLPs) were used to challenge 10 5 human T CEMss cells. Thereafter, cells were washed, treated with trypsin 5 minutes at room temperature (r.t), and the extents of Nef7/GFP entry evaluated by flow cytometry on cells harvested from 3 to 1O h after the challenge.
• TK preserved its activity also upon fusion with Nef7 by transfecting 293T cells with the Nef7/TK expression vector and cultivating them with GCV (not shown). Then, human T lymphoblastoid CEMss cell were challenged with two cycles of 5 ng/10 5 cells of Nef7/TK VLPs.
• Fig. 5 shows the anti-cellular effect of the (VSV-G)Nef7/TK VLPs challenge in CEMss cultivated in the presence of GCV.
• MDM appeared extremely responsive to the (VSV-G) Nef7/TK VLP challenge and GCV treatment, due that a single input of 2 ng of VLPs specifically and reproducibly induced cell death within 4-6 days, depending on the donor source.
• VSV-G Nef7/TK VLP treated cells significantly increased the Annexin-V binding over time, but only when cultivated in the presence of GCV.
• overlapping results were obtained by analyzing MDM from two healthy donors three days after the challenge with 2 ng of VLPs (Fig. 7B).
• Monocytes were isolated by 1 h adherence of PBMC followed by a immune- magnetic depletion of non monocytic cells carried out by means of a selection kit from Miltenyi (Auburn, CA) used following the manufacturer's recommendations. The purity of recovered cell populations was assayed by FACS analysis by means of phycoerithrine (PE)- conjugated anti-CD 14 rnAb (Becton Dickinson, Mountain View, CA) labeling. Cell preparations staining below 95% positive for CD 14 (a cell surface marker specific for monocyte-macrophage cell populations) were discarded. Monocytes were cultured in 48 well plates in RPMI 1640 supplemented with 20% dFCS. Ganciclovir was from Synthex Laboratories, Inc., Palo Alto, CA, and was used at the concentration of 10 to 30 ⁇ M.
• VLP and HIV-I production, infection, and detection Preparations of VLPs pseudotyped with the CD4 and CXCR4 or CCR5 HIV cell receptors were obtained from the supernatants of 293T cells 48-60 h after the calcium phosphate co- transfection of molar equivalent amounts of the pCMV ⁇ R8.74 packaging vector (55), and vectors expressing, respectively, Nef7, Nef7/GFP (72) or Nef7/TK, the human CD4 receptor truncated in its intracytoplasmic domain (73), and either human CXCR4 (74) or CCR5.
• Supernatants were clarified and concentrated by ultracentrifugation on SW 41 rotor, 45,000 g, 1.30 h at 4 0 C. In some instances, the concentrated VLPs were purified through additional ultra-centrifugation (SW 60 rotor, 65,000 g, 4 h at 4°C) on 20% sucrose cushions.
• VLP preparations were titrated both by measuring HIV-I Gag p24 contents by quantitative ELISA (Abbott, Abbott Park, Illinois) and by the reverse transcriptase assay (56). Challenges were performed by spinoculation, i.e., the adsorption of VLPs to cells by means of 1 h of centrifugation at 150 g at r.t. Afterwards, the cells were re-fed by adding fresh medium complemented or not with GCV. In Nef7-GFP VLP internalization experiments, cells were washed to eliminate non adsorbed virions, and seeded in complete medium. At different intervals, cells were harvested, treated with trypsin for 5 min at r.t., and finally analyzed by FACs.
• the evaluation of cell mortality was performed by both the trypan blue exclusion dye, and scoring the percentages of labeled cells by FACs after treatment with 5 ⁇ g/ml of propidium iodide (PI).
• PI propidium iodide
• HIV-I viral preparations were obtained from the supernatants of 293T cells 48 hours after the transfection with vectors expressing the T-tropic NL4-3 (75) or the M-tropic ADA (76) HIV-I genomes. Supernatants were clarified and concentrated by ultracentrifugation as described (72). HIV-I titrations were performed as for VLP preparations. For the recovery of pseudotyped HIV-I, 293T cells were co-transfected with the pNL4-3 molecular clone and a VSV-G expressing vector in a 5:1 molar ratio. Supernatants were harvested 48 h thereafter, clarified and concentrated by ultracentrifugation
• VLP associated products a pool of strongly reactive HIV-I positive sera, ARP 444 sheep anti-Nef 14 antiserum, (University of Leeds, Leeds, UK), anti human CD4 mAb, clone 1F6 (Novacastra, Newcastle, UK), anti-human CXCR4 mAb clone C-20 (Santa Cruz Biotechnology, Santa Cruz, CA), and anti-human CCR5 niAb clone H-185 (Santa Cruz Biotechnology).
• MDM were treated with Permeafix (Ortho Diagnostic, Raritan, NJ) for 30 min at r.t., and then labelled for 1 h at r.t. with a 1:50 dilution of phycoerythrin (PE)- conjugated anti-p24
• HIV-I Gag KC-57 mAb (Coulter Corp. Hialeah, FL).
• Example 1 We have already shown in Example 1 that the VLP-mediated intracellular delivery of Nef7/TK led to cell death in the presence of GCV.
• VLPs specifically directed to HIV infected cells. This was carried out by inserting HIV cell receptors, i.e. CD4 and CXCR4 or CCR5, in VLPs that, in this manner, would enter HIV Env expressing cells through the inverse fusion process.
• CD4-CXCR4 and CD4-CCR5 pseudotyped HIV-I based VLPs were recovered from the supernatants of 293T cells transiently transfected with the respective expression vectors as detailed in the experimental procedures.
• Nef7/GFP incorporating VLPs were also produced.
• VLPs were molecularly characterized by Western blot analyses performed on 50 ng of VLPs purified on 20% sucrose cushion.
• VLPs indeed incorporated amounts of Nef7 -based fusion products comparable to Nef7 alone (Fig. 9A-B) as well as the expected cell receptors (Fig. 9C-E).
• Titers of recovered VLPs reached 1-3 ng/ml in supernatants, and 500-1,500 ng/ml after 500 ⁇ concentration.
• the transient transfection on 293T cells appeared a suitable method for producing the amounts of both (CD4-CXCR4) and (CD4-CCR5) Nef7- based VLPs required for both molecular and biological characterizations.
• CD4-CXCR4 and CD4-CCR5 pseudotyped VLPs were able to enter HIV infected cells.
• HIV-I chronically infected 8E5 human T cells (whose Env expression was preventively monitored by FACs, Fig. 10A) were infected with (CD4-5 CXCR4) or, as control, (CD4) Nef7/GFP VLPs. Cells were then sampled at 3, 6 and 10 hours post infection, treated with trypsin to eliminate VLPs still bound to the cell membrane, and analyzed by FACs.
• Nef7/GFP VLPs were carried out on 293T cells transfected with the M-tropic ADA HIV-I expressing molecular clone. The levels of Env expression were monitored 48 hours thereafter (Fig. 10B) to ensure that the large majority of cells expressed the HIV-I receptor. Thereby, the cells were challenged with (CD4-CCR5) Nef7-GFP VLPs or, as control, with the counterpart carrying the CD4 receptor alone. Similarly to that observed for the T-tropic infected cells, GFP- fluorescent cells were detected within ADA HIV-I expressing cells challenged with (CD4-CCR5) but not with (CD4) Nef7/GFP VLPs (Fig.
• Nef/TK VLPs can specifically kill HIV expressing cells
• HIV-I Acutely Infected Human T Lymphocytes are Targeted by (CD4-CXCR4) Nefl/TK VLPs
• CEM-GFP i.e., a human T lymphoblastoid cell line expressing the GFP exclusively in the presence of Tat
• T-tropic NL4-3 HIV-I strain Two days thereafter, i.e. the time required for the appearance of HIV-I Env markers on the cell membrane (not shown), the cells were extensively washed and challenged twice with 30 ng/10 5 cells of (CD4- CXCR4) VLPs. Thereafter, cells were cultivated in the presence or in the absence of GCV, and after additional five days, scored by FACs for the percentages of fluorescent (i.e.
• Fig. 12 shows that the challenge with (CD4-CXCR4) VLPs coupled with the GCV treatment led to a lack of infected cells till the HIV-I input of 5 ng of HIV-1/10 5 cells. By increasing the HIV-I input, despite HIV-I infected cells became detectable, the relative percentages appeared constantly reduced compared with control conditions.
• VLP -unchallenged HIV-I -infected cells cultured with or without GCV supported the HIV-I replication as well as the VLP-challenged cells re-cultured in the absence of GCV (not shown).
• HIV-I Spread is Inhibited in Human Primary Monocyte/Macrophages Treated with (CD4-CCR5) Nefi/TK VLPs
• T lymphocytes Besides activated T lymphocytes, monocyte/macrophages, dendritic cells and resting T cells are natural host cells for HIV. These are non-replicating cells where the virus establishes a latent/persistent infection leading to the in vivo formation of privileged sites where the virus efficiently resists the HAART therapies. Being the presence of " facilitiesuaries” sites a major bottleneck towards the HIV eradication, it appears of major importance finding new anti-HIV therapeutic approaches efficiently targeting non-replicating, infected cells. In this respect, we sought to evaluate the efficiency of Nef7/TK VLPs in inhibiting the viral spread in a rather relevant in vitro model, i.e. the HIV-I infected human primary monocyte-derived macrophages (MDM).
• MDM human primary monocyte-derived macrophages
• Monocytes were purified from the peripheral blood of healthy donors, cultured for 5 days, and infected with 100 pg/10 5 cells of the ADA M-tropic HIV-I strain. Two days thereafter, cells were washed, challenged twice with 30 ng of (CD4-CCR5) Nef7/TK VLPs, and cultivated in the presence of GCV. Supernatants were harvested from 7 days post-HIV infection and the Gag p24 levels herein measured. As shown in Fig. 13 A, the challenging with CD4-CCR5 VLPs efficiently prevented the viral spread within the MDM cultures cultivated with GCV (Fig. 5A).
• VLP-untreated MDM re-cultured with or without GCV replicated HIV-I as efficiently as the (CD4-CCR5) VLP-treated MDM re-cultured in the absence of GCV (data not shown).
• VLPs specifically target and kill HIV-I Env-expressing cells.
• VLPs appeared effective in clearing HIV-I infected MDM. Hence, such VLPs may be considered a new potential therapeutic tool for combating persistent/latent HIV infections in view of an effective strategy of HIV eradication.
• the HIV-I Nef7 mutant was previously inserted in the pCNefsg25GFP construct expressing the Nef-GFP fusion product by replacing the wt Nef open reading frame (78).
• the GFP moiety of the Nef7-GFP construct was then replaced by the MAGE- A3 open reading frame PCR amplified from the LM3TN plasmid using the following primers: forward 5' CTT GTA GCT AGC CCT CTT GAG CAG AGG AGT CAG CAC 3', and reverse 5'GTA TCT AGA TCA CTC TTC CCC CCT CTC 3'.
• Nef7-MAGE-A3 VLPs were obtained from supernatants of 293T cells 48-60 h after the calcium phosphate co-transfection with the pCMVDR8.74 packaging vector, the Nef7-MAGE-A3, and a plasmid expressing either the VSV-G or the RDl 14 receptors, in a molar ratio of 3:3:1.
• Supernatants were filtered on 0.45 ⁇ m pore size membrane, and concentrated by ultra-centrifugation on a 20% sucrose cushion.
• VLP preparations were then titrated both by measuring HIV-I p24 contents by quantitative ELISA, and by the reverse transcriptase assay.
• Dendritic cells were generated from peripheral blood mononuclear cells (5x107 cells/T25 flask) by Ih adherence at 37 0 C. After that the adherent cells were cultivated in the presence of IL-4 (500 U/ml) and GM-CSF (800 U/ml) in RPMI 1640 medium 10% FBS for 5 days.
• IL-4 500 U/ml
• GM-CSF 800 U/ml
• VLPs Nef7/MAGE-3 VSV-G HIV-VLP, Nef7/MAGE-3 MLV-VLP and Nef7/MAGE-3 RDl 14 HIV-VLP
• PBS PBS
• spinoculation 30' of centrifugation at 2000rpm at room temperature.
• the cells were re-fed by adding fresh medium and were incubated for 12h at 37 0 C
• IFN- ⁇ assay Autologous DCs (3x104) loaded with VLPs as described above, were washed with PBS and seeded in 96-microwell plates with the anti-MAGE-3 CTL (104 cells/well) in IMDM 10% human plasma in the presence of IL-2 (50 U/ml).
• DCs were loaded as described above and used to stimulate a M AGE-3 -specific CTL.
• a specific IFN- ⁇ release was observed in the presence of the loaded DCs regardless of the VLPs origin (MLV, HIV), while unloaded DCs were not recognized.
• Nef is a virion protein. J. Virol. 70, 4283-4290 (1996).
• Nef protein Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 219, 228-236 (1996).
• Nef increases infectivity of HIV via lipid rafts. Curr. Biol. 11: 875-879. 61. Zheng, Y. H., Plemenitas, A., Fielding, C. J., and Peterlin, B. M. (2003). Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-I progeny virions. Proc. Natl. Acad. Sci. U. S. ⁇ 100: 8460-8465.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Genetics & Genomics (AREA)
• Medicinal Chemistry (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Nanotechnology (AREA)
• Cell Biology (AREA)
• Pharmacology & Pharmacy (AREA)
• Gastroenterology & Hepatology (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Biomedical Technology (AREA)
• Crystallography & Structural Chemistry (AREA)
• Veterinary Medicine (AREA)
• Virology (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Medical Informatics (AREA)
• Microbiology (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Toxicology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34586809

Family Applications (1)

Country Status (3)

Families Citing this family (6)

Family Cites Families (2)

• 2005
  • 2005-04-06 GB GBGB0507003.2A patent/GB0507003D0/en not_active Ceased
• 2006
  • 2006-04-05 WO PCT/IB2006/001058 patent/WO2006106435A2/en not_active Application Discontinuation
  • 2006-04-05 EP EP06744593A patent/EP1976866A2/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events